Peptide-Based Prodrug Approaches for Cancer Nanomedicine.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-12-16 Epub Date: 2024-11-27 DOI:10.1021/acsabm.4c01364

Nisar Ul Khaliq, Laraib Amin, Saad Ul Khaliq, Anam Amin, Samreen Omer, Ihtisham Ul Khaliq, Yejin Kim, Joohyeon Kim, Taeho Kim, Dongseong Seo, Daekyung Sung, Hyungjun Kim

{"title":"Peptide-Based Prodrug Approaches for Cancer Nanomedicine.","authors":"Nisar Ul Khaliq, Laraib Amin, Saad Ul Khaliq, Anam Amin, Samreen Omer, Ihtisham Ul Khaliq, Yejin Kim, Joohyeon Kim, Taeho Kim, Dongseong Seo, Daekyung Sung, Hyungjun Kim","doi":"10.1021/acsabm.4c01364","DOIUrl":null,"url":null,"abstract":"<p><p>Peptide-based prodrugs, such as peptide-drug conjugates (PDCs), are currently being developed for cancer therapy. PDCs are considered single-component nanomedicines with various functionalities. The peptide moieties provide stability to the PDCs, which self-assemble into nanostructures in an aqueous medium. Several PDCs based on peptide moieties have been developed for targeted cancer therapy, prevention of multidrug resistance (MDR), and theranostic applications. Based on this information, next-level strategies have been developed to deliver therapeutics and diagnostics to tumor tissues. The induction of apoptosis-targeted therapy is a conceptual approach that has evolved. In this context, smart PDCs have been designed and explored to overcome tumor heterogeneity. This review highlights strategies for the targeted delivery of small molecules and theranostic applications. Moreover, a conceptual approach to induce apoptosis-targeted therapy was exploited through the delivery of smart PDC nanomedicines and their composites.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"8163-8176"},"PeriodicalIF":4.6000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsabm.4c01364","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Peptide-based prodrugs, such as peptide-drug conjugates (PDCs), are currently being developed for cancer therapy. PDCs are considered single-component nanomedicines with various functionalities. The peptide moieties provide stability to the PDCs, which self-assemble into nanostructures in an aqueous medium. Several PDCs based on peptide moieties have been developed for targeted cancer therapy, prevention of multidrug resistance (MDR), and theranostic applications. Based on this information, next-level strategies have been developed to deliver therapeutics and diagnostics to tumor tissues. The induction of apoptosis-targeted therapy is a conceptual approach that has evolved. In this context, smart PDCs have been designed and explored to overcome tumor heterogeneity. This review highlights strategies for the targeted delivery of small molecules and theranostic applications. Moreover, a conceptual approach to induce apoptosis-targeted therapy was exploited through the delivery of smart PDC nanomedicines and their composites.

查看原文本刊更多论文

基于肽的癌症纳米药物原药方法。

目前正在开发基于肽的原药，如肽-药物共轭物（PDCs），用于癌症治疗。PDCs 被认为是具有各种功能的单组分纳米药物。肽分子为 PDCs 提供了稳定性，PDCs 可在水介质中自组装成纳米结构。目前已开发出几种基于肽分子的 PDC，用于癌症靶向治疗、预防多药耐药性（MDR）和治疗应用。基于这些信息，已开发出向肿瘤组织输送治疗药物和诊断药物的新策略。诱导细胞凋亡靶向疗法是一种不断发展的概念性方法。在此背景下，人们设计并探索了智能 PDC，以克服肿瘤的异质性。本综述重点介绍了小分子靶向递送策略和治疗应用。此外，还探讨了通过智能 PDC 纳米药物及其复合材料的递送诱导细胞凋亡靶向治疗的概念方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.